CDK4 and neoplasm: CDK4/6 inhibitors, designed to inhibit uncontrolled cellular proliferation, made tumor types with better efficacy and few adverse effects in which CDK4/6 plays a key role in G1-to-S-phase cell-cycle transition to be targeted (9).